TABLE 2.
Summary of CC50, EC50, and SI values of the compounds against BIRFLU during pretreatment in MDCK cellsa
| Compound | Activity statistics of compound against BIRFLUb
|
||||
|---|---|---|---|---|---|
| CC50 (MTT) (μM) | CC50 (XTT) | EC50 (μM) | SI (MTT) | SI (XTT) | |
| AmA | >50.00 | <2.54 nM | 0.14 | >357.14 | <0.02 |
| BRQ | >50.00 | >50.00 μM | >50.00 | 1.00 | 1.00 |
| 6-Azauridine | 42.66 | > 50.00 μM | 0.55 | 77.56 | >90.91 |
| Azaribine | 19.66 | >50.00 μM | 0.28 | 70.12 | >178.57 |
| PF | 33.35 | >50.00 μM | 0.16 | 208.43 | >312.50 |
| AVN-944 | 29.61 | >50.00 μM | 4.66 | 6.35 | >10.72 |
| MMF | >50.00 | >50.00 μM | >50.00 | 1.00 | 1.00 |
| MPA | >50.00 | >50.00 μM | >50.00 | 1.00 | 1.00 |
| Ribavirin | >50.00 | >50.00 μM | >50.00 | 1.00 | 1.00 |
a
BIRFLU, A/Puerto Rico/8/34 H1N1.
b
CC50, median 50% cytotoxicity concentration; EC50, median 50% effective concentration; SI, selective index (CC50/EC50).